Core Insights - Qiagen reported revenue of $533.54 million for the quarter ended June 2025, reflecting a 7.5% increase year-over-year and surpassing the Zacks Consensus Estimate of $524.1 million by 1.8% [1] - Earnings per share (EPS) for the quarter was $0.60, consistent with the consensus estimate, compared to $0.57 in the same quarter last year [1] Revenue Performance - Diagnostic solutions - NeuMoDx: $3 million, a decrease of 57.1% year-over-year, below the estimated $4.27 million [4] - Diagnostic solutions - QIAstat-Dx: $34 million, exceeding the estimate of $32.08 million, with a year-over-year increase of 41.7% [4] - Diagnostic solutions - QuantiFERON: $129 million, slightly above the estimate of $127.14 million, representing a 12.2% year-over-year increase [4] - Other product sales: $22 million, significantly above the estimate of $16.12 million, marking a 57.1% increase year-over-year [4] - PCR / Nucleic acid amplification: $80 million, in line with the estimate of $80.33 million, showing a 5.3% year-over-year increase [4] - Genomics / NGS: $59 million, below the estimate of $61.81 million, with a 1.7% year-over-year increase [4] - Overall diagnostic solutions: $206 million, exceeding the estimate of $200.88 million, reflecting an 11.4% year-over-year increase [4] - Sample technologies: $166 million, slightly above the estimate of $164.15 million, with a 1.2% year-over-year increase [4] - Other diagnostic solutions: $40 million, surpassing the estimate of $36.95 million, with a 2.6% year-over-year increase [4] Stock Performance - Qiagen's shares have returned 5.7% over the past month, outperforming the Zacks S&P 500 composite's 1% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Core Viewpoint - Wall Street analysts predict that Qiagen (QGEN) will report quarterly earnings of $0.50 per share, reflecting a year-over-year increase of 6.4%, with revenues expected to reach $464.04 million, a 1.1% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, indicating that analysts have not revised their initial projections [2]. - Revisions to earnings estimates are crucial as they serve as indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [3]. Revenue and Sales Forecasts - Analysts forecast 'Sales by Product Groups- Diagnostic solutions- QIAstat-Dx' to reach $30.15 million, indicating a year-over-year change of +20.6% [5]. - 'Sales by Product Groups- Diagnostic solutions- QuantiFERON' is expected to reach $111.16 million, reflecting a year-over-year increase of +10.1% [5]. - The average prediction for 'Sales by Product Groups- Sample technologies' is $150.54 million, suggesting a year-over-year decrease of -2.9% [6]. - 'Sales by Product Groups- Diagnostic solutions' is projected to be $180.35 million, indicating a year-over-year increase of +6.1% [6]. - 'Sales by Product Groups- Diagnostic solutions- NeuMoDx' is expected to reach $4.60 million, reflecting a significant year-over-year decrease of -48.9% [7]. - 'Sales by Product Groups- Genomics / NGS' is projected at $54.60 million, indicating a slight decrease of -0.7% from the prior year [7]. - 'Sales by Product Groups- PCR / Nucleic acid amplification' is expected to reach $67.64 million, reflecting a year-over-year decrease of -0.5% [8]. - 'Revenue- Molecular Diagnostics' is anticipated to be $252.58 million, indicating a year-over-year increase of +3.5% [8]. - The consensus estimate for 'Revenue- Life Sciences' stands at $211.17 million, reflecting a year-over-year decrease of -1.8% [9]. - 'Sales by Product Groups- Diagnostic solutions- Other' is expected to be $34.45 million, indicating a year-over-year decrease of -1.6% [9]. Stock Performance - Qiagen shares have shown a return of +6.2% over the past month, compared to the Zacks S&P 500 composite's +11.5% change, with a Zacks Rank 2 (Buy), suggesting that QGEN is expected to outperform the overall market in the near future [9].